Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 13/20 | 0.32 |
| ▸ | JAK1 | P23458 | 13/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.30 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24676283 | 0.70 | NR1H2 (0.62) | NR1H2ESR2MAPK1 | |
| SCHEMBL6336837 | 0.69 | LIPG (0.48) | NR1H2ESR2MAPK1LIPG | |
| SCHEMBL21577588 | 0.68 | ESR2 (0.37) | NR1H2ESR2MAPK1LIPG | |
| SCHEMBL21577582 | 0.64 | ESR2 (0.43) | NR1H2ESR2MAPK1 | |
| SCHEMBL3050216 | 0.62 | LIPG (0.51) | NR1H2ESR2MAPK1LIPG | |
| SCHEMBL3050326 | 0.61 | LIPG (0.50) | NR1H2ESR2MAPK1LIPG | |
| SCHEMBL21577586 | 0.61 | MAPT (0.41) | NR1H2ESR2MAPK1LIPGJAK2 | |
| SCHEMBL8363017 | 0.60 | ESR2 (0.48) | NR1H2ESR2MAPK1LIPG | |
| SCHEMBL24773078 | 0.60 | NR1H2 (0.62) | NR1H2ESR2MAPK1 | |
| SCHEMBL3616837 | 0.59 | ESR2 (0.47) | NR1H2ESR2MAPK1LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | Frequency Therapeutics, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | MKI67, PROX1, DCX | NR1H2 3221/4885ESR2 2125/4885MAPK1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.